COVID-19 VACCINATION IN MANITOBA TECHNICAL BRIEFING - March 3, 2021
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
COVID-19 VACCINATION IN MANITOBA
TECHNICAL BRIEFING
March 3, 2021
OPERATIONAL UPDATES
VACCINE DELIVERY MODEL UPDATES
Winnipeg Brandon Thompson
SUPERSITES
In larger centres, supersites 6,945 1,473 350
allow for rapid and large-scale DOSES ADMINISTERED DOSES ADMINISTERED DOSES ADMINISTERED
IN LAST WEEK
vaccination for increased IN LAST WEEK IN LAST WEEK
speed and efficiency.
39,649 5,279 350
TOTAL DOSES TOTAL DOSES TOTAL DOSES
ADMINISTERED ADMINISTERED ADMINISTERED
777 165 116
AVG. DAILY DOSES AVG. DAILY DOSES AVG. DAILY DOSES
55 27 14
3 EST. DAILY STAFF (FTE) EST. DAILY STAFF (FTE) EST. DAILY STAFF (FTE)VACCINE DELIVERY MODEL UPDATES
FOCUSED • FITs will visit 120 congregate living facilities this week and administer
about 4,800 residents
IMMUNIZATION • More than 7,800 second-doses in personal care home immunization
TEAMS (FITs) campaign
FITs visit facilities to deliver
vaccines where people live. • All regional health authorities have scheduled prioritized congregate living
sites this week.
4WORKFORCE RECRUITMENT
DAILY OPERATIONAL SCHEDULE Overall, staffing is down due to lack of vaccine
RBC CONVENTION CENTRE KEYSTONE CENTRE FIT TEAM - Winnipeg
1060 Doses 256 Doses 535 Doses
71 31 12
TOTAL STAFF (FTE) TOTAL STAFF (FTE) TOTAL STAFF (FTE)
31 Immunizers (FTE) 12 Immunizers (FTE) 12 Immunizers (FTE)
CURRENT WORKFORCE
2,224 165
•
•
1,647 immunizers
20 clinic managers
STAFF • 27 clinical leads
As of March 1, 2021 this week • 426 navigators
• 104 observers
5COVID-19 DOSE DELIVERY SCHEDULE
Doses Received & Projected
60.0 K
50.0 K
40.0 K
30.0 K
20.0 K
10.0 K
0.0 K
14-Dec- 21-Dec- 28-Dec- 15-Mar- 22-Mar- 29-Mar-
4-Jan-21 11-Jan-21 18-Jan-21 25-Jan-21 1-Feb-21 8-Feb-21 15-Feb-21 22-Feb-21 1-Mar-21 8-Mar-21 5-Apr-21 12-Apr-21 19-Apr-21 26-Apr-21
20 20 20 21 21 21
Moderna Doses 0.0 K 7.3 K 0.0 K 0.0 K 7.4 K 0.0 K 0.0 K 8.1 K 0.0 K 0.0 K 6.1 K 0.0 K 20.5 K 0.0 K 40.6 K 0.0 K 0.0 K 0.0 K 0.0 K 0.0 K
Pfizer Doses 2.3 K 11.7 K 1.2 K 7.0 K 9.4 K 9.4 K 0.0 K 2.3 K 3.5 K 15.2 K 17.6 K 16.4 K 16.4 K 14.0 K 14.0 K 14.0 K 0.0 K 0.0 K 0.0 K 0.0 K
Total 2.3 K 19.0 K 1.2 K 7.0 K 16.8 K 9.4 K 0.0 K 10.4 K 3.5 K 15.2 K 23.7 K 16.4 K 36.9 K 14.0 K 54.6 K 14.0 K 0.0 K 0.0 K 0.0 K 0.0 K
As of March 2, 2021SUPERSITE Closing Stock Balance - Supersites
INVENTORY 12,000 16,000
MANAGEMENT
14,000
10,000
12,000
8,000
10,000
Projected for the next 30 days
6,000 8,000
6,000
4,000
4,000
2,000
2,000
0 -
2021-02-28
2021-03-01
2021-03-02
2021-03-03
2021-03-04
2021-03-05
2021-03-06
2021-03-07
2021-03-08
2021-03-09
2021-03-10
2021-03-11
2021-03-12
2021-03-13
2021-03-14
2021-03-15
2021-03-16
2021-03-17
2021-03-18
2021-03-19
2021-03-20
2021-03-21
2021-03-22
2021-03-23
2021-03-24
2021-03-25
2021-03-26
2021-03-27
2021-03-28
RBC Supersite Keystone Supersite Thompson Supersite Total
Projections as of March 2. Each rise in doses represents a scheduled delivery.
7DOSE ADMINISTRATION PROJECTION
• Based on current Daily Doses Administered - Projection
Does not include doses allocated to First Nations
supply projections, 4,000 140,000
we estimate an
3,500 120,000
3,000
average of 2,277 2,500
100,000
injections per day in 2,000
80,000
March, subject to
60,000
1,500
current vaccine
40,000
1,000
supply forecasts. 500 20,000
- -
Supersites FIT (Pfizer for WRHA, Moderna for other RHAs) Total Cumulative
Projected as of March 2
8LOW-RANGE SCENARIO
Based on Pfizer and Moderna
vaccines.
Allocation details on
AstraZeneca have not been
provided to Manitoba yet.
Projected as of March 2
9HIGH-RANGE SCENARIO
Based on Pfizer, Moderna,
AstraZeneca and other vaccines
that have not yet been approved
Projected as of March 2
10DELIVERING 1.5 MILLION DOSES
SECOND
Daily
• Manitoba continues to report Site / Approach Maximum
QUARTER
Capacity
Daily Maximum Capacity
Supersites
EXPANSION • This shows how many doses
(RBC, Backup Site, Keystone,
Thompson, Vaxport)
6,499
Building from Manitoba's could be delivered on any
small, deliberate and safe given day in Manitoba if we Distributed Model 5,000
starting point to deliver the had adequate supply.
largest immunization Focused
500
campaign in provincial Immunization Teams
• This will be updated as
history
new facilities and staff are
Pop-up Clinics 500
added to increase capacity.
Current Daily
Maximum Capacity 12,499
TARGET CAPACITY Q2 20,000
12CONTINUED Protecting Manitobans, Building Capacity
PROGRESS
• First general • Morden supersite to open mid-
population immunizations on March
March 1
• PCH 2nd dose campaign complete
• Regular expansions of eligibility
criteria • Congregate living facility 1st dose
campaign underway
• Vaxport pilot project underway
• Selkirk supersite opens March 8,
appointments being booked now
13VACCINE TECHNOLOGY
COVID-19
Vaccines Approved vaccines: More vaccines expected
to be approved Q2+:
Multiple vaccines in various
stages • Pfizer-BioNTech
approved Dec. 9, 2020 • Johnson & Johnson*
Each approved vaccine, • Moderna approved Dec. • Novavax
particularly those using different 23, 2020 • Sanofi and GSK
technologies, will have different • AstraZeneca/Covishield • Medicago
indications for use
approved Feb. 26, 2021
*FDA approved Johnson & Johnson one-shot vaccine, Janssen, on Feb. 27, 2021.
15Vaccine Supply Supply to Canada is Expected to Increase
• Supply is expected to increase • Over 70,000 doses of mRNA
exponentially in Q2 as more vaccine (Pfizer and Moderna)
vaccines are approved and administered in Manitoba to date
currently-approved vaccines ramp
up production • Supply of AstraZeneca expected
by mid-March
16COVID-19 Vaccine Agreements in Canada
Supplier / Vaccine Technology Platform Doses Status
AstraZeneca Viral vector 20 million Approved Feb. 2021
Moderna mRNA 44 million Approved Dec. 2020
Pifzer-BioNTech mRNA Up to 76 million Approved Dec. 2020
Johnson & Johnson Viral vector Up to 38 million Under review; submitted to
Health Canada Nov. 11, 2020
Medicago Plant-based Up to 76 million Phase III; anticipated to seek
licensure Q3, 2021.
Novavax Subunit protein Up to 76 million Under review; submitted to
Health Canada Jan. 29, 2021
Sanofi and GlaxoSmithKline Subunit protein Up to 72 million Phase II; anticipated to seek
licensure Q4, 2021.
Does not include provincially-procured vaccines
17Vaccinology
• The three vaccines currently • The COVID-19 vaccines use RNA
authorized for use in Canada or DNA that provide the
(Pfizer –Biontech mRNA, Moderna instructions for our immune
mRNA, and Astra Zeneca DNA) system to manufacture the protein
protect us from COVID-19 that causes our immune system to
infection using a different produce protective antibodies and
approach than other, more familiar immune cells.
vaccines.
• For example: The measles
vaccine fuses a weakened live
virus that causes our immune
system to produce protective
antibodies and immune system
cells. Flu vaccines use inactivated
virus to do the same.
18mRNA Vaccines
Pfizer-BioNTech and Moderna • Storage: ultra-frozen (70˚C) for
Pfizer and frozen (-20˚C)
for Moderna
• Authorized ages: 16+ for Pfizer
and 18+ for Moderna
• Schedule: 2 doses, 3-4 weeks
apart.
19mRNA Vaccine
Effectiveness •Both mRNA vaccines were shown to •Emerging ‘real world’ evidence from
be safe and effective in preventing lab the UK, Scotland and Israel suggests
Pfizer-BioNTech and Moderna confirmed COVID-19 infection after that one dose of mRNA vaccine is 70-
two doses (with effectiveness around 80% effective in preventing lab
94-95%). confirmed COVID-19 infection and
also significantly reduced
•However, significant protection hospitalization and death.
started about 12-14 days after the first
dose and may be above 90% in the •Effectiveness against variants of
clinical trials. concern is evolving.
20Viral Vector
(DNA) Vaccines • Storage: Routine at 2˚C to 8˚C
AstraZeneca • Authorized age: 18+
• Schedule: 2 doses, 4-12 weeks
apart (12 weeks preferred)
21Viral Vector
(DNA) Vaccine •Although the initial clinical trial results •Real world data from the United
showed the AstraZeneca vaccine to Kingdom in those 70+ are showing
Effectiveness be moderately effective (around 60%), single dose effectiveness >70% and a
subsequent analysis of the data significant reduction in hospitalization
AstraZeneca
shows that longer intervals between and death.
dose 1 and dose 2 (12 weeks)
resulted in effectiveness >80%. •Data on effectiveness against
variants of concern is evolving.
22Ongoing
Evaluation • Ongoing clinical trials • Provincial table reviews any
reports of AEFI and collaborates
All vaccines continue to be • Ongoing real-world effectiveness with national tables
monitored for safety and studies
effectiveness after they are • Vaccine safety is monitored more
authorized for use • Federal adverse events following closely than any other medical
immunization (AEFI) system intervention
23Which Vaccine
Should I Get? • If you are eligible to be immunized, • Being immunized with one type of
the answer is simple: The first vaccine now will not prevent you
vaccine available to you. from getting another type
of COVID-19 vaccine in the future,
• Locations where you can get when supplies are greater
vaccines will expand, and there will
be more types of vaccines • Get the facts on COVID-19 vaccine
available over time. from reliable sources
• But this is key: All vaccines • Vaccines are safe, effective and
approved for use are effective in are a life-saving intervention
preventing you from getting
COVID-19, and in reducing the
seriousness of your symptoms
24COVID-19 VACCINATION IN MANITOBA
QUESTIONS?
Media are invited to provide feedback on future tech briefings or
specific areas of interest to lenore.kowalchuk@gov.mb.caYou can also read
